APA

Steelman L. S., Navolanic P. M., Sokolosky M. L., Taylor J. R., Lehmann B. D., Chappell W. H., Abrams S. L., Wong E. W. T., Stadelman K. M., Terrian D. M., Leslie N. R., Martelli A. M., Stivala F., Libra M., Franklin R. A. & McCubrey J. A. (20080807). Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. : Oncogene.

Chicago

Steelman L S, Navolanic P M, Sokolosky M L, Taylor J R, Lehmann B D, Chappell W H, Abrams S L, Wong E W T, Stadelman K M, Terrian D M, Leslie N R, Martelli A M, Stivala F, Libra M, Franklin R A and McCubrey J A. 20080807. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. : Oncogene.

Harvard

Steelman L. S., Navolanic P. M., Sokolosky M. L., Taylor J. R., Lehmann B. D., Chappell W. H., Abrams S. L., Wong E. W. T., Stadelman K. M., Terrian D. M., Leslie N. R., Martelli A. M., Stivala F., Libra M., Franklin R. A. and McCubrey J. A. (20080807). Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. : Oncogene.

MLA

Steelman L S, Navolanic P M, Sokolosky M L, Taylor J R, Lehmann B D, Chappell W H, Abrams S L, Wong E W T, Stadelman K M, Terrian D M, Leslie N R, Martelli A M, Stivala F, Libra M, Franklin R A and McCubrey J A. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. : Oncogene. 20080807.